Adverse events78

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 78

Type	Event	Organ system	Group	Affected	At risk
other	Gastrointestinal disorders	Gastrointestinal disorders	Open Treatment Phase 1 ELND005 500 mg BID	29	309
other	Gastrointestinal disorders	Gastrointestinal disorders	Phase 2 Placebo	12	65
other	Gastrointestinal disorders	Gastrointestinal disorders	Phase 2 ELND005 500 mg BID	11	64
other	General disorders and administration site conditions	General disorders	Open Treatment Phase 1 ELND005 500 mg BID	10	309
other	General disorders and administration site conditions	General disorders	Phase 2 Placebo	2	65
other	General disorders and administration site conditions	General disorders	Phase 2 ELND005 500 mg BID	5	64
other	Infections and infestations	Infections and infestations	Open Treatment Phase 1 ELND005 500 mg BID	47	309
other	Infections and infestations	Infections and infestations	Phase 2 Placebo	20	65
other	Infections and infestations	Infections and infestations	Phase 2 ELND005 500 mg BID	20	64
other	Injury poisoning and procedural complications	Injury, poisoning and procedural complications	Open Treatment Phase 1 ELND005 500 mg BID	19	309
other	Injury poisoning and procedural complications	Injury, poisoning and procedural complications	Phase 2 Placebo	15	65
other	Injury poisoning and procedural complications	Injury, poisoning and procedural complications	Phase 2 ELND005 500 mg BID	11	64
other	Investigations	Investigations	Open Treatment Phase 1 ELND005 500 mg BID	13	309
other	Investigations	Investigations	Phase 2 Placebo	8	65
other	Investigations	Investigations	Phase 2 ELND005 500 mg BID	8	64
other	Metabolism and nutrition disorders	Metabolism and nutrition disorders	Open Treatment Phase 1 ELND005 500 mg BID	9	309
other	Metabolism and nutrition disorders	Metabolism and nutrition disorders	Phase 2 Placebo	2	65
other	Metabolism and nutrition disorders	Metabolism and nutrition disorders	Phase 2 ELND005 500 mg BID	5	64
other	Musculoskeletal and connective tissue disorders	Musculoskeletal and connective tissue disorders	Open Treatment Phase 1 ELND005 500 mg BID	18	309
other	Musculoskeletal and connective tissue disorders	Musculoskeletal and connective tissue disorders	Phase 2 Placebo	11	65

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01674010/events

API reference For AI assistants

Adverse events78

Sources 3

Read this list from software.